Video could not be played
Funding Opportunity Announcement
The New York Regional Center for Diabetes Translation Research (NY-CDTR) announces the availability of Pilot and Feasibility (P&F) funding for preliminary studies to support planned future extramural funding applications (NIH preferred) for diabetes-related translational research.
Budget requests can be up to $50,000/year for one year, or up to $25,000/year for 2 years. Given the shortened timeline due to a delay in funding decisions at NIH, preference will be given to one-year awards. Proposals for secondary analyses are encouraged and those seeking datasets should contact us for suggestions. Meritorious proposals for $50,000/year for 2 years will also be considered, with a maximum of one such award granted. A 2nd year of funding is contingent on progress and available program funding.
Content areas of interest include psychosocial aspects of diabetes across the life span, population health and health systems, nutritional science, behavioral science and technology. P&F funds may supplement ongoing funded projects (e.g., K-awards), but non-overlap must be clearly demonstrated in the proposal.
Pilot awards will support research across the translational science spectrum (i.e., bedside to clinical practice and community settings, dissemination and implementation research). Proposals should use translational science principles and may involve implementation/dissemination science, natural experiments, quantitative, qualitative, or mixed methods. Secondary analyses of pertinent data sets, observational studies, or clinical trials are acceptable, and should remain within the scope of the budget and timeline of the award. Community and other stakeholder engagement in the development or ongoing work of the project is encouraged.
Eligibility
Must hold a faculty appointment at the time of award (postdoctoral fellows are not eligible). This program is designed to support (in order of priority):
- New investigators and early-stage investigators (ESIs). In this category are investigators shifting from mentor-based research to an independent career. Meritorious proposals from these investigators receive the highest priority for funding.
- Established investigators, in other research areas or cross-disciplinary research, who wish to apply their expertise to diabetes. High-risk, high-reward proposals receive priority.
- NY-CDTR members who wish to explore a new area of innovative research that constitutes a substantive departure from their previous or ongoing externally funded diabetes research.
Application Process
A Letter of Intent is highly encouraged, consisting of a one-paragraph overview of your primary research question and study design to confirm programmatic fit, and should be emailed to the program director no later than September 8th, 2026. Consultations from the directors and NY-CDTR Core Faculty are available to you as you develop your application (Email us!).
Full applications should be emailed to the program director and the center coordinator by November 2nd, 2026 and must: 1) clearly delineate the rationale and aims of the research 2) describe rigorous study procedures; 3) include sample size justification and a data analysis plan; 4) describe use of NY- CDTR Core resources; and 5) discuss how the proposed research will support a future application for external funding (NIH preferred). In-kind ongoing consultation and mentorship are available to awardees. Pilot funding may be used to support PI effort at a minimal level (<10%). INDIRECT COSTS ARE NOT ALLOWED. We encourage you to utilize the NY-CDTR core resources and services available to awardees. More information can be found on our website.
No internal grant forms or approval signatures are needed to submit an application. However, IRB approval is needed for protection of human subjects if the proposal is selected for funding. Required application components are detailed in #9 on the following FAQs. You are encouraged to identify appropriate reviewers and submit their names and email addresses with your application. Submit the application components as a single Word or PDF document. Please use relevant NIH PHS 398 grant application forms, which can be downloaded from the NIH website
More questions? Contact keyla.ordonez@einsteinmed.edu or jeffrey.gonzalez@yu.edu. We look forward to hearing from you!
Earliest start date forsuccessful applications: January 1st, 2027
FAQs
No, but P&F awardees are generally NY Regional CDTR members or are from institutions at which a NYCDTR member is based. Psychosocial, health psychology and behavioral medicine proposals are accepted from investigators across the country, regardless of membership status, through our National Resource Core.
You can find the NY-CDTR Core services. These in-kind resources and services can supplement your award.
Institutional resources for facilitating research vary by institution. At Einstein-Montefiore, relevant resources and services for clinical and translational research are described here
Yes, but in-kind limited consultative biostatistical services are available, as feasible, from the NY-CDTR. At Einstein-Montefiore, consultation is also available from the ICTR’s Biostatistics, Epidemiology & Research Design Core. Limited funds may also be included for publication fees or travel for a conference presentation.
Budgets should be developed in accordance with NIH policy regarding patient care costs.
NO. Per NY-CDTR policy, indirect costs (IDC) are not allowable for these pilot funds. If your administrator has IDC questions, please refer them to shaunice.dawkins@einsteinmed.edu. No exceptions will be made.
Yes, if an early-stage or mid-career investigator is working with another investigator, e.g., in a team science model, then an MPI situation may be acceptable. Please query the P&F program director to check on appropriate PI models. Please keep in mind the limited funding for investigator salary support.
Your proposal should include a clear explanation of how the pilot funding supports a different aspect not covered by your K-award. There must be NO overlap. Many awardees have successfully navigated this.
p>The proposal should be on the NIH 398 template and include: 1) Abstract; 2) Specific Aims (1 page max); 3) Research Approach (5 pages max) should address Significance, Innovation, Study Procedures, Sample Size Justification and Data Analysis Plan, Planned Use of NY-CDTR Core Resources, Study Timeline, and How Proposed Research Will Support Future Funding Application (NIH preferred); 4) Literature Cited; 5) Detailed Budget; 6) Budget Justification; 7) NIH Biosketches and Other Support for all key personnel; 8) Indicate whether you qualify for new investigator status in diabetes translation research or early-stage investigator status. (See: https://grants.nih.gov/policy-and-compliance/policy-topics/early-stage-investigators)
10. What else is required of me if my proposal is selected for NY-CDTR P&F grant funding?
The NIH requires IRB approval for human subjects research or noted exemption prior to receiving funding (See: https://grants.nih.gov/policy/humansubjects.htm). If applicable, Data Use Agreements must also be in place prior to the award. PHS Human Subjects and Clinical Trials information is required for yearly progress reporting: Data and Safety Monitoring Plan (if applicable, model will be provided); Dissemination Plan (model will be provided); Statistical Design and Power (model will be provided); Narrative on activities, progress, milestones, and outcomes (model will be provided); Registering the study on clinicaltrials.gov, if applicable; and Planned and Actual enrollment and inclusion data. You will also be asked to participate in yearly workshops and seminars for NY-CDTR P&F awardees.